---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-030012"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:32:53.534236+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Pharma shareholders approve share increase to 125M, reject Lincoln Park issuance and officer exculpation

## Summary
- Shareholders approved amendment to increase authorized common stock from 75M to 125M, effective June 12.
- Shareholders rejected proposed issuance of shares to Lincoln Park Capital in excess of 19.99% of outstanding.
- Shareholders rejected charter amendment to exculpate officers.
- Board adopted amended bylaws with enhanced procedural rules for stockholder nominations and proposals.
- All seven director nominees elected; Ernst & Young ratified as auditor; say-on-pay advisory approved.

## SEC filing metadata
- accession: 0001140361-24-030012
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036124030012/0001140361-24-030012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036124030012/ef20031101_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-030012
- JSON: https://secwatch.observer/filing/0001140361-24-030012.json
- Plain text: https://secwatch.observer/filing/0001140361-24-030012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.